Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010254 | 0.77 | GSR (0.42) | GSRRNPEPCPB2CPB1FOLH1 | |
| SCHEMBL6010252 | 0.77 | GSR (0.42) | GSRRNPEPCPB2CPB1FOLH1 | |
| SCHEMBL6028111 | 0.76 | GSR (0.47) | GSRRNPEPCPB2GABRR1CPB1 | |
| SCHEMBL6028109 | 0.76 | GSR (0.47) | GSRRNPEPCPB2GABRR1CPB1 | |
| SCHEMBL1854666 | 0.75 | GSR (0.54) | GSRRNPEPCPB2GABRR1CPB1 | |
| SCHEMBL1854667 | 0.75 | GSR (0.54) | GSRRNPEPCPB2GABRR1CPB1 | |
| SCHEMBL9289262 | 0.72 | NOD1 (0.40) | GSRCPB2 | |
| SCHEMBL472903 | 0.72 | NOD1 (0.40) | GSRCPB2 | |
| SCHEMBL2993448 | 0.72 | GSR (0.43) | GSRRNPEPCPB2FOLH1LMNA | |
| SCHEMBL2993454 | 0.72 | GSR (0.43) | GSRRNPEPCPB2FOLH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | US | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | GSR 1728/4885RNPEP 2516/4885CPB2 2032/4885 |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | GSR 1803/4885RNPEP 96/4885CPB2 85/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | GSR 3830/4885RNPEP 108/4885CPB2 211/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | GSR 2970/4885RNPEP 820/4885CPB2 563/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | GSR 2621/4885RNPEP 124/4885CPB2 166/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | GSR 1803/4885RNPEP 96/4885CPB2 85/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | GSR 3020/4885RNPEP 202/4885CPB2 496/4885 |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | ADORA1, ADORA3, ADORA2A | GSR 684/4885RNPEP 1413/4885CPB2 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.